Actively Recruiting
A Follow-up Study to Evaluate the Safety of ALLO-ASC-CD in ALLO-ASC-CD-101 Clinical Trial
Led by Anterogen Co., Ltd. · Updated on 2023-08-25
9
Participants Needed
2
Research Sites
528 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is an open-label follow up study to evaluate the safety for the subjects with ALLO-ASC-CD injection in phase 1 clinical trial (ALLO-ASC-CD-101) for 36 months.
CONDITIONS
Official Title
A Follow-up Study to Evaluate the Safety of ALLO-ASC-CD in ALLO-ASC-CD-101 Clinical Trial
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Subjects who received ALLO-ASC-CD injection in the phase 1 clinical trial ALLO-ASC-CD-101
- Ability to provide written informed consent before starting the study
- Willingness and ability to comply with all study requirements
You will not qualify if you...
- Subjects deemed unsuitable for the study by the principal investigator
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
Seoul National University Hospital
Seoul, South Korea, 03080
Actively Recruiting
2
Severance Hospital
Seoul, South Korea, 03722
Completed
Research Team
J
Jae Hee Cheon, Ph D
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here